New treatments for HIV-1 in patients with tuberculosis in South Africa

Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa

NIH-funded research Centre/aids Programme/res/south Africa · NIH-11143963

This study is looking at how well certain HIV medications work for people who also have tuberculosis, especially in South Africa where many have both infections, and it aims to find the best and safest ways to use these treatments for both adults and kids.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCentre/aids Programme/res/south Africa NIH-funded
Lab location1 site (Durban, SOUTH AFRICA)
Project IDNIH-11143963 on NIH RePORTER

What this research studies

This research investigates the effectiveness of second-generation integrase strand transfer inhibitors (InSTIs) like dolutegravir and bictegravir for treating HIV-1 in patients who are also being treated for tuberculosis (TB). Given the high rates of HIV and TB co-infection in South Africa, the study aims to determine safe and effective dosing strategies for both adults and children, particularly those under 20 kg. The research will assess how these medications interact with rifampicin, a common TB treatment, to ensure optimal care for patients with these dual infections.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals diagnosed with HIV-1 who are also undergoing treatment for tuberculosis, particularly those in South Africa.

Not a fit: Patients without HIV-1 or those not undergoing treatment for tuberculosis may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment options for patients with HIV-1 and TB co-infection, enhancing their health outcomes.

How similar studies have performed: Previous research has shown success with integrase strand transfer inhibitors in treating HIV, but this specific approach for co-infected patients is novel.

Where this research is happening

Durban, SOUTH AFRICA

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Acquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome Virus
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.